secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001000694-25-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B
-------------------------------------------------------------------------------

- Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.
- Raises full-year adjusted total revenue framework to $975M-$1,025M (from $300-$350M).
- FDA BLA review on track; approval triggers $175M milestone from Sanofi; MAs to Sanofi by Q4 2025.
- Strengthened Takeda partnership: $20M upfront, annual milestones plus royalties on Japan sales.
- SHIELD-Utah: Nuvaxovid recipients had ~39% fewer reactogenicity symptoms vs mRNA vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/0001000694-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/nvax-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001000694-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer